Literature DB >> 12061906

Serotonin type-4 receptors modulate the sensitivity of intramural mechanoreceptive afferents of the cat rectum.

A Schikowski1, Michael Thewissen, C Mathis, H-G Ross, P Enck.   

Abstract

It has been suggested that serotonin (5-hydroxytryptamine) type-4 (5-HT4) receptors modulate the sensitivity of intrinsic afferents of the intestinal mucosa. We studied the involvement of 5-HT4receptors in the modulation of extrinsic afferent sensitivity of the intestinal wall. During distension ramps, mechanoreceptive rectal afferents in sacral dorsal roots were examined in decerebrate anaesthesia-free cats using the selective 5-HT4receptor partial agonist, tegaserod (HTF 919), and the 5-HT4receptor antagonist, SB 203186. The static discharge rate of the afferents evoked by rectal distension decreased after intravenous (i.v.) administration of tegaserod at intraluminal pressures above 30 mmHg, with the most effective reduction occurring at 50 mmHg. The effect was dose-dependent, with maximal reduction occurring at 1.2 mg kg-1 bodyweight, and could be partly reversed by i.v. administration of SB 203186. Tegaserod did not alter the pressure-volume relationship (compliance) of the rectum. It is tentatively concluded that 5-HT4receptor activation has an inhibitory effect on intramural mechanoreceptors in the cat's rectum. Our results are in line with the observation that tegaserod relieves the sensory symptoms of patients suffering from irritable bowel syndrome.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12061906     DOI: 10.1046/j.1365-2982.2002.00328.x

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  23 in total

Review 1.  Pharmacology of serotonin: what a clinician should know.

Authors:  F De Ponti
Journal:  Gut       Date:  2004-10       Impact factor: 23.059

2.  The effects of 5-HT4 receptor agonist, mosapride citrate, on visceral hypersensitivity in a rat model.

Authors:  Jae Woong Lee; Ki Woon Sung; Oh Young Lee; Seo Eun Lee; Chong Il Sohn
Journal:  Dig Dis Sci       Date:  2012-03-17       Impact factor: 3.199

Review 3.  Early investigational therapeutics for gastrointestinal motility disorders: from animal studies to Phase II trials.

Authors:  Nelson Valentin; Andres Acosta; Michael Camilleri
Journal:  Expert Opin Investig Drugs       Date:  2015-06       Impact factor: 6.206

4.  Visceral analgesic effect of 5-HT(4) receptor agonist in rats involves the rostroventral medulla (RVM).

Authors:  Jyoti N Sengupta; Aaron Mickle; Pradeep Kannampalli; Russell Spruell; John McRorie; Reza Shaker; Adrian Miranda
Journal:  Neuropharmacology       Date:  2013-12-12       Impact factor: 5.250

5.  Tegaserod inhibits noxious rectal distention induced responses and limbic system c-Fos expression in rats with visceral hypersensitivity.

Authors:  Hong-Mei Jiao; Peng-Yan Xie
Journal:  World J Gastroenterol       Date:  2004-10-01       Impact factor: 5.742

6.  Long-term tegaserod treatment for dysmotility-like functional dyspepsia: results of two identical 1-year cohort studies.

Authors:  William D Chey; Colin W Howden; Jan Tack; Gregory Ligozio; David L Earnest
Journal:  Dig Dis Sci       Date:  2009-12-03       Impact factor: 3.199

Review 7.  Structure activity relationship of synaptic and junctional neurotransmission.

Authors:  Raj K Goyal; Arun Chaudhury
Journal:  Auton Neurosci       Date:  2013-03-25       Impact factor: 3.145

Review 8.  Role of serotonin in the pathophysiology of the irritable bowel syndrome.

Authors:  Michael D Crowell
Journal:  Br J Pharmacol       Date:  2004-04       Impact factor: 8.739

Review 9.  Benefit-risk assessment of tegaserod in irritable bowel syndrome.

Authors:  Richard Lea; Peter J Whorwell
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 10.  The role of serotonin in irritable bowel syndrome: implications for management.

Authors:  Brian Garvin; John W Wiley
Journal:  Curr Gastroenterol Rep       Date:  2008-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.